Sep 10, 2021 / 06:00PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Great. Good afternoon, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Adagene with us for the next session.
Before we get started, I need to read a quick disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/research disclosure.
So with that, pleased to introduce Peter Luo, the CEO of Adagene. And Peter, I know you want to make some opening comments, so I'll turn it over to you for that. And then we can get into Q&A.
Peter P. Luo - Adagene Inc. - Co-Founder, CEO & Chairman of the Board
Thanks, Matthew. And thanks, everyone, for your time. And today, I'd like to take this opportunity to walk you through a few highlights about Adagene.
And here the investment highlights, I'd like to walk you
Adagene Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers